SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX

SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ:IMTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 208,456 shares of the company’s stock, valued at approximately $2,189,000. SG Americas Securities LLC owned about 0.17% of Immatics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in IMTX. Bank of America Corp DE grew its position in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares in the last quarter. Insigneo Advisory Services LLC bought a new stake in shares of Immatics in the 3rd quarter worth approximately $103,000. Engineers Gate Manager LP bought a new stake in shares of Immatics in the 2nd quarter worth approximately $124,000. Verition Fund Management LLC acquired a new stake in shares of Immatics during the 3rd quarter worth approximately $385,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Immatics by 8.3% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock worth $406,000 after purchasing an additional 3,666 shares in the last quarter. Institutional investors own 64.41% of the company’s stock.

Wall Street Analysts Forecast Growth

IMTX has been the subject of a number of recent research reports. Mizuho set a $25.00 target price on Immatics in a research note on Thursday, February 19th. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group started coverage on shares of Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $19.00.

Immatics Price Performance

Immatics stock opened at $10.35 on Friday. The business has a 50 day simple moving average of $9.84 and a 200 day simple moving average of $9.77. The company has a market capitalization of $1.39 billion, a PE ratio of -5.62 and a beta of 1.34. Immatics N.V. has a one year low of $3.30 and a one year high of $12.41.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.14. The firm had revenue of $23.00 million during the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%. Equities analysts anticipate that Immatics N.V. will post -0.72 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.